Cargando…

CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL

It was previously believed that patients with Ph-like ALL had poorer prognosis compared with other B-ALL subgroups due to resistance to conventional chemotherapy and lack of targeted drugs. CAR-T therapy has been successfully applied in the treatment of relapsed and refractory B-ALL. Currently, ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Hai-ping, Kong, Dan-qing, Shen, Hong-jie, Cui, Wei, Wang, Qian, Li, Zheng, Yin, Jia, Kang, Li-qing, Yu, Lei, Wu, De-pei, Tang, Xiao-wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930301/ https://www.ncbi.nlm.nih.gov/pubmed/36793095 http://dx.doi.org/10.1186/s40364-023-00451-2

Ejemplares similares

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL
por: Aldoss, Ibrahim, et al.
Publicado: (2022)

Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant
por: Liu, Pengjiang, et al.
Publicado: (2020)

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL
por: Qiu, Yan, et al.
Publicado: (2023)

Efficacy and influencing factors of allogeneic hematopoietic stem cell transplantation in treatment of 71 children with leukemia
por: Zhang, Bing-Lei, et al.
Publicado: (2019)

Immunoglobulin and granulocyte-colony stimulating factor affecting infection and hematopoietic reconstruction in allogeneic hematopoietic stem cell transplantation
por: Ma, Le, et al.
Publicado: (2023)

Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL
por: Wieduwilt, Matthew J., et al.
Publicado: (2021)

Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation
por: Chen, Juan, et al.
Publicado: (2023)

Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation
por: Meissner, Julia, et al.
Publicado: (2022)

Cerebral toxoplasmosis after allogeneic hematopoietic stem cell transplantation diagnosed by megagenomic analysis
por: Shen, Kai, et al.
Publicado: (2019)

Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation
por: Mascarenhas, Kristen, et al.
Publicado: (2019)

Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant
por: Zhao, Chenchen, et al.
Publicado: (2022)

HLA-E expression constitutes a novel determinant for ALL disease monitoring following hematopoietic stem cell transplantation
por: Reusing, Sarah B., et al.
Publicado: (2021)

Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
por: Yang, Fan, et al.
Publicado: (2022)

CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation
por: Calderin Sollet, Zuleika, et al.
Publicado: (2023)

Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades
por: Nishiwaki, Satoshi, et al.
Publicado: (2022)

Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
por: Pophali, Prateek, et al.
Publicado: (2020)

A case of lupus miliaris disseminatus faciei after allogeneic hematopoietic stem cell transplantation
por: Zhang, Si, et al.
Publicado: (2019)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Low Toxicity and Favorable Overall Survival in Relapsed/Refractory B-ALL following CAR T cells and CD34-selected T Cell Depleted Allogeneic Hematopoietic Cell Transplant.
por: Fabrizio, Vanessa A., et al.
Publicado: (2020)

Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia
por: Hassan, Mona Ali, et al.
Publicado: (2023)

Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Mamez, Anne-Claire, et al.
Publicado: (2021)

First allogeneic hematopoietic stem cell transplantation in RASGRP1 deficiency: long-term follow-up
por: Kuskonmaz, Baris, et al.
Publicado: (2022)

Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant
por: Pabon, Cindy M., et al.
Publicado: (2021)

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
por: Liu, Jun, et al.
Publicado: (2017)

Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients
por: Wu, Xi, et al.
Publicado: (2022)

MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell Transplantation
por: Zhang, Xin-Yue, et al.
Publicado: (2021)

Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma
por: Yang, Luxin, et al.
Publicado: (2018)

The preceding hyponatremia is a useful hallmark for the diagnosis of HHV-6 encephalitis after allogeneic hematopoietic stem cell transplantation
por: Yoshida, Shota, et al.
Publicado: (2022)

A novel full-human CD22-CAR T cell therapy with potent activity against CD22(low) B-ALL
por: Tan, Yue, et al.
Publicado: (2021)

Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL?
por: Couto, Samuel C. F., et al.
Publicado: (2023)

Paraplegia as Manifestation of an Isolated Central Nervous System Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in a Woman with Acute Myelogenous Leukemia
por: Yang, Bi-Hui, et al.
Publicado: (2016)

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study
por: Schetelig, Johannes, et al.
Publicado: (2020)

Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma
por: Peng, Yin-yin, et al.
Publicado: (2021)

Viral Dynamics of SARS-CoV-2 in Critically Ill Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients with COVID-19
por: Roedl, Kevin, et al.
Publicado: (2021)

Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
por: Lee, Jong-Mi, et al.
Publicado: (2023)

Co-occurrence of Multiple Sclerosis and Severe Aplastic Anemia: A Report of Two Cases Successfully Treated with Allogeneic Hematopoietic Stem Cell Transplantation
por: Haroon, Alfadil, et al.
Publicado: (2023)

Outcome of adult T-lymphoblastic lymphoma depends on ALL-type chemotherapy, prognostic factors, and performance of allogeneic hematopoietic stem cell transplantation
por: Hu, Meiwei, et al.
Publicado: (2018)

T-ALL Cells as Tool Cells for CAR T Therapy
por: Ren, Anqi, et al.
Publicado: (2023)

Annotations for all by all - the BioSapiens network
por: Thornton, Janet
Publicado: (2009)

Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case report
por: Li, Meng-Yun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ebtn2kgpe47ig8i03fr4743k7k